Health Condition 1: B20- Human immunodeficiency virus [HIV]disease Health Condition 2: A150- Tuberculosis of lung
Conditions
Interventions
Control Intervention1: nil: nil
Sponsors
Dr Puneet Paliwal
Eligibility
Inclusion criteria
Inclusion criteria: 1.Cases of adverse drug reactions due to anti-tubercular and antiretroviral therapy. 2.Patients more than 18 years with Pulmonary TB, EPTB or disseminated TB.
Exclusion criteria
Exclusion criteria: 1.Cases having incompletely filled adverse drug reaction details will be excluded from the study. 2.Treatment defaulters or death within 15 days of ATT. 3.Any other diagnosis other than TB after starting treatment. 4.Cases who do not give consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To study the frequency of adverse drug reactions in patients receiving anti-tubercular ( ATT ) and antiretroviral drugs ( ART ) every 4 to 6 weeks. 2.To study the nature of adverse drug reactions in Patients receiving anti-tubercular ( ATT ) and antiretroviral drugs ( ART ) and to characterize ADR according to type , Severity and time of occurrence every 4 to 6 weeks Timepoint: 18 months | — |
Secondary
| Measure | Time frame |
|---|---|
| • To compare clinical and therapeutic details in serious and non serious cases of adverse drug reactions due to anti-tubercular and antiretroviral drugs. Timepoint: 18 months | — |
Countries
India
Contacts
Public ContactDr Syed Ziaur Rahman
Jawahar lal nehru medical college and hospital
Outcome results
None listed